Gilead Sciences Inc. (GILD)

68.15
NASDAQ : Health Technology
Prev Close 70.19
Day Low/High 67.89 / 70.00
52 Wk Low/High 64.27 / 89.54
Avg Volume 6.80M
Exchange NASDAQ
Shares Outstanding 1.29B
Market Cap 90.80B
EPS 3.50
P/E Ratio 56.15
Div & Yield 2.28 (3.21%)

Latest News

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) For Treatment Of Chronic Hepatitis C Virus Genotype 1-6

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) For Treatment Of Chronic Hepatitis C Virus Genotype 1-6

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) in China for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection...

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy ® (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a...

Kite Announces Updated Data From ZUMA-3 Study Of KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite Announces Updated Data From ZUMA-3 Study Of KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite, a Gilead Company (Nasdaq: GILD), announced updated results from ZUMA-3, a single-arm Phase 1/2 study evaluating KTE-X19 (formerly KTE-C19), an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy, in adult patients with relapsed or...

Kite Announces Two-Year Data For Yescarta® (Axicabtagene Ciloleucel) In Patients With Refractory Large B-Cell Lymphoma

Kite Announces Two-Year Data For Yescarta® (Axicabtagene Ciloleucel) In Patients With Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

China National Medical Products Administration (NMPA) Approves Gilead's Vemlidy® (Tenofovir Alafenamide) For Chronic Hepatitis B Virus (HBV) Infection

China National Medical Products Administration (NMPA) Approves Gilead's Vemlidy® (Tenofovir Alafenamide) For Chronic Hepatitis B Virus (HBV) Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Vemlidy ® (tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults and adolescents (aged...

Gilead Sciences To Present At The Evercore ISI HealthCONx Conference On Tuesday, November 27

Gilead Sciences To Present At The Evercore ISI HealthCONx Conference On Tuesday, November 27

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.

Gilead Presents Latest Data From Viral Hepatitis Research Programs At The Liver Meeting® 2018

Gilead Presents Latest Data From Viral Hepatitis Research Programs At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ®...

Gilead Announces Positive Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis (PSC) At The Liver Meeting® 2018

Gilead Announces Positive Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis (PSC) At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients...

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program For Advanced Fibrosis At The Liver Meeting® 2018

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program For Advanced Fibrosis At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the company's clinical development program for advanced fibrosis due to nonalcoholic steatohepatitis (NASH).

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead has been trying to turn things around but few see that turn coming anytime soon.

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Gilead To Present Latest Scientific Research In Hematologic Malignancies And Solid Tumors At ASH 2018

Gilead To Present Latest Scientific Research In Hematologic Malignancies And Solid Tumors At ASH 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from its oncology and cell therapy research programs will be presented at the 60 th American Society of Hematology (ASH) Annual Meeting & Exposition, in San Diego from December 1 - 4, 2018.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Gilead Sciences And Tango Therapeutics Announce Strategic Collaboration To Develop Next-Generation Targeted Immuno-Oncology Therapies

Gilead Sciences And Tango Therapeutics Announce Strategic Collaboration To Develop Next-Generation Targeted Immuno-Oncology Therapies

Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics, Inc.

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1490) evaluating the safety and efficacy of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg...

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

Gilead Sciences Announces Fourth Quarter 2018 Dividend

Gilead Sciences Announces Fourth Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Third Quarter 2018 Financial Results

Gilead Sciences Announces Third Quarter 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter ended September 30, 2018.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Is the Fed on Course?: Cramer's 'Mad Money' Recap (Wednesday 10/17/18)

Is the Fed on Course?: Cramer's 'Mad Money' Recap (Wednesday 10/17/18)

Jim Cramer evaluates the Federal Reserve's interest-rate moves and says it's right to stay focused on any form of inflation.

Gilead Sciences, KeyCorp, Ventas: 'Mad Money' Lightning Round

Gilead Sciences, KeyCorp, Ventas: 'Mad Money' Lightning Round

Jim Cramer weighs in on Gilead Sciences, KeyCorp, Ventas, Weight Watchers, Del Taco Restaurants, Hanesbrands, Kraft Heinz and more.

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

Jim Cramer says traders hate hearing about long-term investing because they want instant payoffs.

General Electric, Chevron, Manitowoc: 'Mad Money' Lightning Round

General Electric, Chevron, Manitowoc: 'Mad Money' Lightning Round

Jim Cramer takes a look at General Electric, Chevron, Manitowoc, Gilead Sciences, Encore Capital Group, Tower Semiconductor, Camping World, Kinder Morgan and more.

The Apple Revolution: Cramer's 'Mad Money' Recap (Thursday 9/13/18)

The Apple Revolution: Cramer's 'Mad Money' Recap (Thursday 9/13/18)

Jim Cramer says sustained, revolutionary innovation creates new demand where it didn't exist before.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis Both Published In The Lancet

Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis Both Published In The Lancet

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis...

Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis To Be Presented At 2018 ACR/ARHP Annual Meeting

Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis To Be Presented At 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely...

TheStreet Quant Rating: C (Hold)